Insider purchases at Xeris Biopharma keep shareholders on edge.

Individual insider purchases are often no reason for excitement. However, insiders at Xeris Biopharma seem to be increasingly investing in the company's shares, which sends a positive message to shareholders. Although it is not advisable to simply follow the example of insiders, one should still keep an eye on their buying and selling decisions. In the past twelve months, one transaction stood out: Chief Operating Officer Steven Pieper purchased shares worth $55,000 at a price of $1.95 per share. Given the current price of $2.94, this purchase offers little insight into whether insiders consider the current price attractive. Notably, in the last twelve months, only purchase transactions have been recorded, with no sales. The Lead Independent Director John Schmid recently bought shares worth $20,000. Such purchases, without any sales, are generally positive; however, the investments made in the last quarter are not substantial enough to draw conclusions solely based on them. An interesting aspect remains the total number of shares held by insiders. At Xeris Biopharma, they own 4.8% of the company, which corresponds to a value of approximately $21 million. Although this share is not exceptionally high, it does suggest a certain alignment of interests between management and shareholders. In the last three months, only limited insider purchases have been recorded. This is not encouraging, yet the transaction balance of the past year remains encouraging. Insiders do not seem to have doubts about the company's situation, a positive aspect for all shareholders of the biopharma company. In addition to the transactions, one should not overlook the upcoming challenges. During research, experts identified two warning signs, one of which is even considered potentially serious. However, those seeking alternative investment opportunities will find exciting companies to choose from here.